Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OVCON-35 vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation, and increases cervical mucus viscosity, impeding sperm penetration.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Prevention of pregnancy
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet (35 mcg ethinyl estradiol and 0.4 mg norethindrone) orally once daily.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Ethinyl estradiol: 5-18 hours (mean ~12 hours, biphasic); norethindrone: 5-14 hours (mean ~8 hours). Terminal half-life relevant for once-daily dosing.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Ethinyl estradiol is primarily metabolized by CYP3A4; norethindrone is metabolized via reduction and sulfate conjugation, partly involving CYP3A4.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Renal 60% (metabolites, glucuronide conjugates), fecal 10%, biliary 5%, remainder via other pathways.
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Ethinyl estradiol: 97-98% (mainly albumin, SHBG); norethindrone: 90-95% (albumin, SHBG).
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Ethinyl estradiol: 2-4 L/kg; norethindrone: 4-6 L/kg. Large Vd indicates extensive tissue distribution.
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Ethinyl estradiol: ~38-48% (first-pass metabolism); norethindrone: ~64% (range 47-73%).
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No dose adjustment required for mild-to-moderate renal impairment. Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of hyperkalemia.
No data available for fictional drug ALYACEN 777.
Contraindicated in severe hepatic disease (Child-Pugh Class C) and active liver disease. Use with caution in Child-Pugh Class A or B; dose adjustment not established.
No data available for fictional drug ALYACEN 777.
Safety and efficacy not established in children under 18 years. Postmenarchal adolescents: same as adult dosing, but weigh risks vs. benefits.
No data available for fictional drug ALYACEN 777.
Not typically used in postmenopausal women. Contraindicated in women over 60 due to increased risk of thromboembolic events and hypertension.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age and with heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use combination oral contraceptives.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Increased risk of thromboembolic disorders, myocardial infarction, stroke, and hepatic neoplasia,Discontinue if jaundice, visual disturbances, or migraine headaches develop,May cause fluid retention; use with caution in conditions that might be aggravated by fluid retention,May decrease glucose tolerance; monitor diabetic patients,May cause elevation in blood pressure,Hereditary angioedema may be exacerbated
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Pregnancy,Active liver disease or benign/malignant liver tumors,Heavy smoking in women over 35
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
No specific food interactions. However, grapefruit juice may increase ethinyl estradiol levels by inhibiting CYP3A4; avoid excessive consumption. Cranberry juice may increase warfarin effect if taken concurrently, but no direct interaction with OVCON-35. Take with food or milk to reduce nausea.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
FDA Pregnancy Category X. First trimester: increased risk of neural tube defects, congenital heart defects, and limb reduction defects. Second and third trimesters: fetal feminization in males, vaginal adenosis in females, and other urogenital anomalies. Postnatal: increased risk of neurodevelopmental issues.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Contraindicated in breastfeeding. Estrogens and progestins are excreted in breast milk. M/P ratio not established. May reduce milk production and quality.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
Contraindicated in pregnancy; no dose adjustment applies. Use is contraindicated once pregnancy is confirmed. Discontinue immediately.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
OVCON-35 is a combined oral contraceptive (COC) containing norethindrone 0.4 mg and ethinyl estradiol 35 mcg. It has higher progestin dose relative to estrogen, making it suitable for women with estrogen-related side effects. Monitor for breakthrough bleeding, particularly in early cycles. Contraindicated in women with BMI > 35 due to increased thromboembolic risk. Consider interaction with CYP450 inducers (e.g., rifampin) which may reduce contraceptive efficacy. Use with caution in migraine with aura due to stroke risk.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one tablet daily at the same time to maintain hormone levels and prevent pregnancy.,If you miss a pill, follow the instructions in the package insert or consult your healthcare provider. Missing pills increases pregnancy risk.,Common side effects include nausea, breast tenderness, headache, and breakthrough bleeding. These often improve after 2-3 cycles.,This medication does not protect against sexually transmitted infections (STIs). Use barrier protection.,Inform your doctor of all medications, especially antibiotics, anticonvulsants, or St. John's Wort, as they may reduce effectiveness.,Seek immediate medical attention if you experience severe leg pain, chest pain, sudden shortness of breath, or severe headache (signs of blood clots or stroke).,Do not smoke while using this medication, especially if over 35 years old; smoking increases risk of serious cardiovascular side effects.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OVCON-35 vs ALYACEN 777, answered by our medical review team.
OVCON-35 is a Oral Contraceptive that works by Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation, and increases cervical mucus viscosity, impeding sperm penetration.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OVCON-35 and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OVCON-35 is: One tablet (35 mcg ethinyl estradiol and 0.4 mg norethindrone) orally once daily.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OVCON-35 and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OVCON-35 is classified as Category C. FDA Pregnancy Category X. First trimester: increased risk of neural tube defects, congenital heart defects, and limb reduction defects. Second and third trimesters: fetal feminizat. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.